GENISTEIN is a naturally occurring isoflavone that was initially described as a tyrosine kinase inhibitor (1) and has subsequently been found to inhibit topoisomerase II (24) , histone kinase (13) , and P 1 -purinergic receptors (27) . Genistein has also been shown to regulate a number of ion transporters including the Na (26, 39) , voltage-gated K ϩ channels in vascular smooth muscle (36) , the Ca 2ϩ -dependent K ϩ conductance in rat distal colon (6), a K ϩ channel in the basolateral membrane of epithelial cells (16) , the Na ϩ /H ϩ exchanger (7) , and the multidrug resistanceassociated protein 1 (38) . Illeck et al. (18) were the first to show that in contrast to its inhibitory actions, genistein at low concentrations (Յ50 M) could activate the cystic fibrosis transmembrane conductance regulator (CFTR) expressed in NIH/3T3 fibroblasts. Further studies have shown that genistein stimulates CFTR-mediated Cl Ϫ secretion in the shark rectal gland (21) , in cell lines derived from human colonic epithelia (15, 16, 32) , and in Hi-5 insect cells (40) . These reports all conclude that genistein increases CFTR-mediated Cl Ϫ secretion without increasing the intracellular concentration of either cAMP ([cAMP] i ) or Ca 2ϩ ([Ca 2ϩ ] i ). Initial studies by Lehrich and Forrest (21) and Illeck et al. (18) both suggested that genistein activates CFTR through inhibition of tyrosine kinase pathways, acting either directly on CFTR or on regulators of CFTR. Further work by Reenstra et al. (31) , Illeck et al. (16) , and Yang et al. (42) showed that a basal level of protein kinase A (PKA) activity is required for activation of CFTR by genistein. They concluded that genistein acted by inhibiting phosphatases. Reenstra et al. (31) showed that the level of CFTR phosphorylation increased under stimulation by genistein. Illeck et al. (16) demonstrated that whereas genistein does not increase [cAMP] i , it does require cellular cAMP to regulate CFTR. More recent experiments have provided evidence that genistein binds directly to CFTR, most probably in one or both of the nucleotide binding domains, although binding to another domain cannot be excluded (8, 15, 40, 41) . It has been demonstrated that genistein binds to the nucleotide binding folds of the tyrosine kinase HCK (35) and topoisomerase II (24) . The current data suggest that CFTR activation by genistein involves binding of genistein to CFTR and prior phosphorylation of the regulatory domain by PKA (8, 15, 40) . The variability in genistein-mediated Cl Ϫ secretion in different cell systems and its differing reliance on rising intracellular cAMP levels could be explained by different basal levels of PKA activity giving different basal levels of CFTR phosphorylation. In some cases this level of phosphorylation may not be sufficient to allow CFTR activation by genistein without additional phosphorylation by cAMP-stimulated PKA activity.
Recently, Illeck and Fischer (15) have shown that genistein and other naturally occurring flavonoids activate CFTR-mediated Cl Ϫ secretion in Calu-3 monolayers and stimulate in vivo nasal potential difference by almost 28% of the isoproterenol response. Hwang et al. (14) Ϫ secretion in the trachea and colon and that the increase is dependent on the presence of the CFTR channel.
MATERIALS AND METHODS

Animals.
Tissues were taken from Cambridge CF null Cftr tm1Cam or ⌬F508 Cftr tm2Cam mouse stocks. Both lines are maintained as outbred stocks (129Sv/Ev ϫ MF1). Wild-type tissues were taken from either ϩ/ϩ or ϩ/Ϫ mice and treated as one group because no statistical difference was found between these genotypes. More wild-type mice than CF or ⌬F508 mice were used in this study; therefore, this group consists of littermates of CF and ⌬F508 mice used in the study and aged-matched mice from other litters. Because the stocks are outbred, mice from many different matings were studied to ensure that results were representative of the electrophysiological status of the whole stock. CF tissues were taken from mice homozygous for either the CF null mutation or the ⌬F508 mutation. The mice were between 40 and 105 days old, except for four mice used for null tracheal measurements, which were between 330 and 356 days old. The tracheas of these four mice showed no differences in their response to drugs compared with the response of CF null mice 41-62 days old.
Measurement of electrogenic transepithelial ion movement by I sc . Mice were killed by exposure to a rising concentration of CO 2 . The trachea was removed and stripped of connective tissue and muscle, opened longitudinally, and mounted in an Ussing chamber so that a surface area of 2.3 mm 2 was exposed. The muscle layer was stripped from the distal colonic epithelium, which was mounted in an Ussing chamber so that a surface area of 20 mm 2 was exposed. A parafilm washer was placed between the two halves of the Ussing Chamber to reduce edge damage. The tissue was bathed on each side by 20 ml of Krebs-Henseleit solution (KHS) maintained at 37°C and gassed with 95% O 2 -5% CO 2 . Tissues were short circuited using a WPI DVC-1000 voltage clamp (World Precision Instruments, Stevenage, UK). Changes in voltage were monitored by calomel electrodes placed in a reservoir of 3 M KCl and linked to the Ussing chamber by KHS-filled polythene tubes, the ends of which were plugged with 3 M KCl-1.5% agarose. Current was passed from the WPI clamp using Ag-AgCl electrodes via 3 M KCl-agar bridges. 7.4 when maintained at 37°C and bubbled with 95% O 2 -5% CO 2 .
Drugs. Amiloride (Sigma) was made as a 10 mM stock solution in water and was used at a final concentration of 100 M. Genistein (synthetic, Sigma) was made as a 100 mM stock solution in DMSO and was used at a final concentration of 50 or 100 M. A-23187 (Sigma) was kept as a 1 mM stock solution in 95% ethanol and was used at 1 M. 2,5-Di-tertbutyl-hydroquinone (TBHQ; Aldrich) was made as a 25 mM stock solution in 95% ethanol and was used at 25 M. Forskolin (Calbiochem) was kept as a 10 mM stock solution in 95% ethanol and was used at a final concentration of 10 M. Furosemide (Sigma) was dissolved in water with a drop of NaOH (ϳ100 l of NaOH in 5 ml of water) to form a stock solution of 100 mM and was used at a final concentration of 1 mM. Diphenylamine-2-carboxylate (DPC; Aldrich) was stored as a 100 mM stock solution in 95% ethanol and was used at a final concentration of 1 mM. 4,4Ј-Diisothiocyanatostilbene-2,2Ј-disulfonic acid (DIDS; Sigma) was made as a 300 mM stock solution in DMSO and was used at a final concentration of 300 M. Glibenclamide (Sigma) was dissolved in DMSO and kept as 1 and 100 mM stock solutions that were used at a final concentration of 1 or 100 M, respectively. Drugs were added sequentially at 10-min intervals, except for A-23187 and TBHQ, which were added together and left for 20 min before further drugs were added.
CFTR gene delivery to CF null mice. CF null mice were anesthetized with Avertin (0.5 g of 2,2,2-tribromoethanol dissolved in 0.63 ml of tertiary amyl alcohol and then diluted 1:50 in PBS) at a dose of 0.017 ml/g body weight. The 100 l of DNA-liposome mix was instilled into the trachea over a 10-min period. The DNA-liposome mix consisted of 10 g of plasmid complexed with 60 g of DC-Chol:DOPE {3␤[N-(NЈ, NЈ-dimethylaminoethane)carbomyl] cholesterol:dioleoylphosphatidyl ethanolamine} (9) in a Krebs-HEPES pH 9.0 diluent. The charge ratio of the complex is 1.98 . Mice received one of two plasmids. pTRIAL10CFTR2 (pT10CFTR) contains the human CFTR (hCFTR) cDNA under the control of the Rous Sarcoma Virus 3Ј long-terminal repeat (RSV 3Ј LTR) promoter (22) . pTRAIL10 (pT10) is the plasmid backbone lacking the hCFTR cDNA.
Statistics. Results are presented as means Ϯ SE. Comparisons of results were made using an unpaired, two-tailed Student's t-test. P Ͻ 0.05 was considered significant.
RESULTS
Genistein increases Cl
Ϫ secretion in wild-type tracheas. The effect of genistein on Cl Ϫ secretion in wildtype tracheas was examined ( Fig. 1) . Amiloride (100 M) was always added to the apical membrane before genistein to block Na ϩ absorption by the epithelial Na ϩ channel (ENaC) because electrogenic Na ϩ absorption reduces the electrochemical gradient for Cl Ϫ secretion. Amiloride addition caused a reduction in baseline I sc of Ϫ34.9 Ϯ 7.1 A/cm 2 (n ϭ 15). Bilateral addition of 50 M genistein increased I sc by 16.4 Ϯ 2.8 A/cm 2 (n ϭ 15) (Fig. 1A) . Addition of 50 M genistein to only the apical membrane increased I sc by 22.8 Ϯ 3.6 A/cm 2 (n ϭ 6), which was not significantly different from the increase in I sc when genistein was added to both membranes. Genistin (100 M), an inactive form of genistein (1), produced no change in I sc when added bilaterally (n ϭ 4, data not shown).
The response to 50 M genistein could not be augmented by increasing the phosphorylation level of CFTR before genistein addition. The addition of either 100 nM forskolin or 1 M IBMX, after amiloride, produced I sc increases of 12.9 Ϯ 3.1 (n ϭ 5) and 12.3 Ϯ 3.7 A/cm 2 (n ϭ 7), respectively. Genistein produced a similar further increase in I sc after both drugs, 14.6 Ϯ 3.6 A/cm 2 after forskolin (n ϭ 5) and 15.2 Ϯ 5.0 A/cm 2 after IBMX (n ϭ 7). These responses are not significantly different from the response to genistein without prior addition of low concentrations of forskolin or IBMX.
The effect of Cl Ϫ channel blockers on the genistein response was studied. DPC (1 M) (2) inhibited all of the genistein-induced I sc increase and part of the basal I sc , suggesting that a proportion of the basal I sc was due to Cl Ϫ secretion (Fig. 1A ). Apical addition of 300 M DIDS (2) had no significant effect on genisteinstimulated I sc (mean change Ϫ2.3 Ϯ 2.7 A/cm 2 , n ϭ 6) ( Fig. 1B) . In contrast, apical addition of 100 M glibenclamide (33) inhibited the genistein-sensitive increase in I sc by 84.7 Ϯ 24.2% (n ϭ 7) (Fig. 1B) , whereas addition of 1 M glibenclamide to the apical membrane had no effect on the genistein response (n ϭ 6, data not shown). After genistein was added bilaterally or to the apical membrane only, the Na ϩ -K ϩ -2Cl Ϫ cotransporter inhibitor furosemide (1 mM) inhibited the genistein response by 79.3 Ϯ 14.9% (n ϭ 12) (Fig. 1, C and D) . In Cl Ϫ -free KHS the response to genistein was reduced by ϳ70% to 3.9 Ϯ 2.0 A/cm 2 (n ϭ 8), significantly smaller than the response in normal KHS (P Ͻ 0.01) (Fig. 1D) ) was investigated (Fig. 2) . The response to amiloride (100 M) was similar in wild-type (Ϫ34.9 Ϯ 7.1 A/cm 2 , n ϭ 15) and CF null tracheas (Ϫ26.6 Ϯ 5.2 A/cm 2 , n ϭ 9) (Fig. 2, A and B) . Bilateral addition of 50 M genistein produced no significant change in I sc in the tracheas from CF null mice (0.9 Ϯ 1.1 A/cm 2 , n ϭ 9) (Fig. 2 , B and C). This is highly significantly different from the increase in I sc observed after addition of genistein to wild-type tracheas (P Ͻ 0.0005).
Genistein does not affect Ca representative traces of short-circuit current (I sc ) responses from individual wild-type tracheas. Amiloride was added at 100 M to the apical membrane. Genistein (50 M) was added to both the apical and basolateral membranes (A and B) or to the apical membrane only (apm; C). Diphenylamine-2-carboxylate (DPC, 1 mM), glibenclamide (100 M), and DIDS (300 M) were added to the apical membrane only. Furosemide (1 mM) was added to the basolateral membrane only. D: summary of the effects of various inhibitors on the change in I sc generated by genistein. Values are means Ϯ SE of I sc response to genistein with (ϩ) and without (Ϫ) inhibitor. Genistein (50 M) was added to both membranes except for the group in which the action of furosemide was studied, where genistein was added to either both membranes or the apical membrane only. n ϭ 6 mice for all groups except furosemide (n ϭ 12), glibenclamide (n ϭ 7), and Cl Ϫ free (n ϭ 8). P values are indicated where significant differences were observed.
genistein in both wild-type (56.4 Ϯ 11.6 A/cm 2 , n ϭ 8) and CF null mice (45.1 Ϯ 9.1 A/cm 2 , n ϭ 5) (Fig. 2) . These responses are not significantly different from those observed when these drugs were added before genistein (data not shown). The subsequent addition of 10 M forskolin in wild-type tracheas produced only a small increase in I sc (2.5 Ϯ 1.2 A/cm 2 , n ϭ 8) (Fig. 2,  A and D) . However, when the order of drug addition to a wild-type trachea was reversed after addition of genistein, the forskolin response was 20.5 Ϯ 3.9 A/ cm 2 and the A-23187/TBHQ response was 39.3 Ϯ 6.5 A/cm 2 (n ϭ 8) (Fig. 2D) . The order of drug addition did not significantly alter the response to A-23187/TBHQ; however, the response to forskolin was significantly greater when the drug was added directly after genistein (P Ͻ 0.001) than when added after both genistein and A-23187/TBHQ (Fig. 2D) . When genistein was added directly after forskolin to wildtype tracheas, the genistein produced no further increase in I sc (n ϭ 5, data not shown).
The same effect was observed in CF null tracheas. The addition of forskolin, after both genistein and A-23187/TBHQ, produced no further increase in I sc (Fig. 2B ), but when forskolin was added directly after genistein, it produced an increase in I sc of 29.5 Ϯ 8.6 A/cm 2 (n ϭ 7), and the subsequent addition of A-23187/TBHQ produced a further increase of 34.7 Ϯ 9.0 A/cm 2 (n ϭ 7). In wild-type and CF null tracheas the combined increase in I sc in response to both A-23187/TBHQ and forskolin was independent of the order of drug addition. In wild-type tracheas the total increase in I sc was 59.8 Ϯ 8.5 A/cm 2 after A-23187/ TBHQ followed by forskolin (n ϭ 8) and 56.4 Ϯ 11.6 A/cm 2 after forskolin followed by A-23187/TBHQ (n ϭ 8). In CF null tracheas the increase in I sc was 46.4 Ϯ 6.4 A/cm 2 after A-23187/TBHQ followed by forskolin (n ϭ 7) and 64.3 Ϯ 17.2 A/cm 2 after forskolin followed by A-23187/TBHQ (n ϭ 7). These values are not significantly different.
Delivery of hCFTR cDNA to the airways of CF null mice restores the genistein response in the trachea. CF null mice were transfected with either a hCFTR expression plasmid (pT10CFTR) or empty plasmid vector (pT10) complexed with the liposome DC-Chol:DOPE. Two days after transfection the tracheas were mounted in Ussing chambers for I sc measurements. Tracheas transfected with pT10CFTR showed a genistein-sensitive increase in I sc of 11.2 Ϯ 2.6 A/cm 2 (n ϭ 8) (Fig. 3,  C and D) , which is significantly higher than that in untreated CF null mice (P Ͻ 0.002) and not significantly different from that in wild-type. The trachea of CF null mice transfected with pT10 showed a small genistein-sensitive current of 4.2 Ϯ 1.6 A/cm 2 (n ϭ 7) (Fig. 3D) , which is not significantly different from that in untreated CF null tracheas and significantly smaller than that in tracheas of CF null mice treated with pT10CFTR (P Ͻ 0.05) and in untreated wild-type tracheas (P Ͻ 0.01). The responses to A-23187/TBHQ (CF null ϩ pT10CFTR: 63.1 Ϯ 10.6 A/cm 2 , n ϭ 13; CF null ϩ pT10: 46.4 Ϯ 6.4 A/cm 2 , n ϭ 7) and amiloride (CF null ϩ pT10CFTR: Ϫ40.5 Ϯ 9.6 A/cm 2 , n ϭ 13; CF null ϩ pT10: Ϫ26.6 Ϯ 5.2 A/cm 2 , n ϭ 8) were not significantly different between CF null mice transfected with either plasmid and untreated CF null mice.
Genistein is able to increase I sc responses in some tracheas taken from ⌬F508 mice.
The effect of genistein on tracheas taken from ⌬F508 homozygous mice (Cftr tm2Cam ) (4) was studied (Fig. 4) . Individual tra- Values are means Ϯ SE for wild type (n ϭ 15), CF null (n ϭ 9), CF null ϩ pT10CFTR (n ϭ 8), and CF null ϩ pT10 (n ϭ 7) mice. Drug additions were made as detailed in Fig. 2 . P values are indicated where significant differences were observed. Fig . 4 . The effect of genistein on tracheas from ⌬F508 mice. A and B: representative traces of I sc responses in two individual tracheas taken from ⌬F508 mice. A shows the I sc responses from a trachea that did not respond to the addition of 50 M genistein, whereas B shows a typical response in a trachea that did respond to the addition of genistein. C: combined data for ⌬F508 tracheal responses. When all the ⌬F508 tracheas are grouped together (n ϭ 13), the I sc response to genistein is significantly smaller than the response of wild-type mice (n ϭ 15; P Ͻ 0.02). Values are means Ϯ SE; n ϭ 7 for ⌬F508 "responders" and n ϭ 6 for ⌬F508 "nonresponders." cheas varied in their response to the addition of genistein. Forty-six percent showed no response or a very small response to 50 M genistein (0.26 Ϯ 0.8 A/cm 2 , n ϭ 6) (Fig. 4A) . However, some tracheas responded to genistein at levels similar to those seen in wild-type mice (12.0 Ϯ 2.1 A/cm 2 , n ϭ 7) (Fig. 4B) . Overall, the mean response from all the ⌬F508 tracheas studied was 7.1 Ϯ 1.9 A/cm 2 (n ϭ 13) (Fig. 4C ), significantly smaller than the genistein response in wild-type tracheas (P Ͻ 0.02). The responses to amiloride (Ϫ21.3 Ϯ 3.3 A/cm 2 , n ϭ 13) and A-23187/TBHQ (75.9 Ϯ 12.4 A/cm 2 , n ϭ 13) were not significantly different from those measured in either wild-type or CF null tracheas. Tracheas that did not respond to genistein showed amiloride and A-23187/TBHQ responses similar to those of tracheas that did demonstrate a genistein-induced increase in I sc (data not shown).
The effect of genistein on I sc responses of wild-type, CF null, and ⌬F508 colons.
The effect of genistein on the I sc of colons from wild-type, CF null, and ⌬F508 mice was measured (Fig. 5) . Bilateral addition of 50 M genistein (after amiloride) to wild-type colons resulted in an increase in I sc of 21 (Fig. 5A) . The combined I sc increase of genistein and forskolin was 75.3 Ϯ 11.4 A/cm 2 , which is signif- Fig. 5 . The effect of genistein on colons from wild-type, CF null, and ⌬F508 mice. A: changes (mean Ϯ SE) in I sc following drug addition in colons taken from wild-type, CF null, and ⌬F508 mice. Drugs were added at the following concentrations: amiloride, 100 M, apical membrane only; genistein, 100 M, apical and basolateral membranes; forskolin, 10 M, apical and basolateral membranes; furosemide, 1 mM, basolateral membrane only. The basal I sc and response to amiloride is significantly different in wild-type (n ϭ 8) and ⌬F508 colons (n ϭ 9). The response to forskolin is significantly smaller in CF null colons (n ϭ 10) compared with ⌬F508 colons (n ϭ 9). B: a comparison of the change in I sc in response to forskolin (10 M) only or to genistein (100 M) followed by forskolin (10 M) in wild-type, CF null, and ⌬F508 colons. Amiloride (100 M) was added first in all experiments. Values are means Ϯ SE; wild type: n ϭ 8; CF null: n ϭ 21 (forskolin) and n ϭ 10 (genistein ϩ forskolin); ⌬F508: n ϭ 10 (forskolin) and n ϭ 11 (genistein ϩ forskolin). P values are indicated where significant differences were observed.
icantly lower than the mean response to forskolin alone (P Ͻ 0.02) (Fig. 5B) , n ϭ 9), and 10 M forskolin produced a further decrease of Ϫ6.5 Ϯ 1.2 A/cm 2 in CF null colons (n ϭ 10) and Ϫ14.0 Ϯ 3.0 A/cm 2 in ⌬F508 colons (n ϭ 9) (Fig. 5A) . Forskolin alone decreased I sc by Ϫ24.8 Ϯ 1.5 (CF null, n ϭ 21) or Ϫ17.2 Ϯ 1.5 A/cm 2 (⌬F508, n ϭ 10). In both CF null and ⌬F508 colons, the combined change in response to genistein and forskolin was not significantly different from the change in response to forskolin alone (Fig. 5B) . For both genotypes furosemide completely reversed the change in I sc due to genistein and forskolin (Fig. 5A) . The response to genistein was similar in CF null and ⌬F508 colons, but the response to forskolin after genistein was significantly larger in ⌬F508 colons ( Fig. 5A , P Ͻ 0.05), although the response to forskolin alone is significantly smaller in ⌬F508 colons compared with CF null colons (Ϫ17.2 Ϯ 1.5 A/cm 2 , n ϭ 10 vs. Ϫ24.8 Ϯ 1.5 A/cm 2 , n ϭ 21; P Ͻ 0.005) (Fig. 5B) . However, the ⌬F508 colon response to forskolin after genistein is not significantly different from the ⌬F508 responses to forskolin with no prior genistein.
Both the basal I sc (17.1 Ϯ 4.2 A/cm 2 , n ϭ 9) and the amiloride-sensitive I sc (Ϫ5.0 Ϯ 0.5 A/cm 2 , n ϭ 9) of ⌬F508 colons were significantly smaller than those measured in wild-type colons (basal I sc : 27.0 Ϯ 3.9 A/cm 2 ; amiloride-sensitive I sc : Ϫ10.8 Ϯ 3.1 A/cm 2 , n ϭ 8; P Ͻ 0.05) (Fig. 5A) .
DISCUSSION
Others have shown that genistein can stimulate CFTR Cl Ϫ channels in a variety of cell systems (8, 14-16, 18, 20, 21, 31, 32, 41) . Here we report the first description of the action of genistein on intact murine tissues. Genistein, but not genistin, increased I sc when added to either wild-type tracheal or colonic tissues. A number of experiments were conducted to confirm that this response was due to CFTR-mediated Cl Ϫ secretion.
First, removal of Cl Ϫ from the bathing buffer resulted in a significant decrease (P Ͻ 0.01) in the I sc response to the addition of genistein. The residual small genistein-sensitive I sc may be due to HCO 3 Ϫ secretion through CFTR (20, 25, 37) . Second, the genistein response was inhibited by DPC and glibenclamide but not by DIDS. DPC is a nonspecific Cl Ϫ channel inhibitor that has been shown to inhibit CFTR (2), whereas the sulfonylurea glibenclamide inhibits CFTR at 100 but not 1 M (29, 34) . However, glibenclamide also inhibits the outwardly rectifying Cl Ϫ channel (ORCC) at 100 M (29). Although it is able to block the ORCC at an extracellular concentration of 10 M, up to 500 M extracellular DIDS has no effect on the activity and conductance of CFTR (10). Thus the insensitivity of the genistein response to 300 M DIDS is characteristic of CFTR-mediated Cl Ϫ secretion. Third, the genistein response was inhibited by furosemide, suggesting that the genistein-mediated increase in I sc was due to Cl Ϫ secretion. Finally, when genistein was tested on tracheas taken from CF null mice, which have no functional CFTR, no response was observed. The response to genistein could be restored to wild-type levels by transfecting the tracheas of CF null mice with a plasmid expressing hCFTR. We conclude from these results that genistein activates Cl Ϫ secretion through CFTR in the murine trachea, although we cannot formally rule out the small possibility that Cl Ϫ secretion is through an alternative Cl Ϫ channel whose opening depends on the presence of CFTR. However, this latter possibility is considered unlikely because it has been shown by patch-clamp analysis that genistein activates CFTR in cell systems. Current data suggest that one mechanism of action of genistein is by direct binding to CFTR to promote channel opening, and this requires the presence of ATP and phosphorylation of the R domain (8, 40, 41) . It is interesting to note that in our tracheal studies, prior treatment with a submaximal concentration of forskolin to stimulate CFTR phosphorylation did not augment the genistein response. This is in contrast to studies showing that genistein required the prior addition of low concentrations of forskolin (1 M) to reach the same levels of stimulation seen with 10 M forskolin. In our study, prior addition of low concentrations of forskolin (100 nM) or IBMX (1 M) did not increase the response to genistein, suggesting that the basal phosphorylation state of CFTR in the murine trachea is sufficient to obtain the maximum activation possible by 50 M genistein under the conditions studied. Thus there may be a significant difference between cell systems and fresh tissue in the extent to which CFTR is phosphorylated at the basal level. Illeck et al. (17) have also stated that in the presence of amiloride and/or low-Cl Ϫ buffer, genistein is able to stimulate the in vivo nasal potential difference of humans without the prior addition of isoproterenol. When the prior addition of higher levels of forskolin (1 M) or IBMX (100 M) was tested, it was found that genistein could produce no additional increase in I sc . Thus further elucidation of the combined actions of these drugs to try and understand their mechanism of action is probably limited by the total Cl Ϫ secretory capacity of the tracheal epithelium.
The data support the observation that the response to forskolin is likely to be composed of both cAMP-and Ca 2ϩ -mediated Cl Ϫ secretion (12, 23) , whereas the genistein response is mediated only by CFTR Cl Ϫ secretion. In our study, forskolin added immediately after genistein further increased I sc , whereas forskolin added after genistein and A-23187/TBHQ produced no further increase in I sc . Tracheas taken from ⌬F508 mice showed a bimodal response to genistein, eliciting either no increase in I sc or a secretory response similar to that in wild type. The ⌬F508 mice (like the CF null mice) are maintained as an outbred stock (129Sv/Ev ϫ MF1). It is possible that particular combinations of modifier genes might allow trafficking of the ⌬F508 protein to the apical membrane in some mice, where the channel can be opened by genistein (14, 19) . In mice that did not respond to genistein, one would assume that no ⌬F508 protein had reached the apical membrane. Unfortunately, because of the very low amounts of CFTR protein in the tracheal epithelium, we have been unable to detect either wild-type or ⌬F508 protein in cells of the tracheal epithelium by immunohistochemistry (Ratcliff R, personal communication), so further electrophysiological techniques are required to ascertain whether ⌬F508 protein can reach the tracheal epithelium apical membrane in a subset of ⌬F508 mice.
In the trachea, 50 M genistein was able to elicit an increase in I sc similar to that elicited by 10 M forskolin; however, in the colon, 100 M genistein did not increase I sc to the same level as forskolin. This could be because the basal level of phosphorylation of CFTR is less in the colonic epithelium than in the tracheal epithelium. Consistent with this possibility, Diener and Hug (6) demonstrated that prior addition of 200 nM forskolin to the rat distal colon enhanced the genistein response. In our study the addition of forskolin after genistein treatment produced a further increase in I sc similar in size to the initial increase induced by genistein. However, the total increase in I sc due to genistein and forskolin is still lower than the increase generated by forskolin alone. Diener and Hug (6) concluded that genistein interacts in synergy with the cAMP-mediated Cl Ϫ secretion of the colon but antagonistically with Ca 2ϩ -dependent K ϩ conductance. They showed that genistein inhibits carbachol-mediated K ϩ conductance. This would explain why the genistein and forskolin I sc responses are lower than expected, because if genistein inhibits basolateral K ϩ conductance, this will reduce the driving force for Cl Ϫ secretion across the apical membrane. Also, it is clear from the results of the CF null and ⌬F508 colons that genistein activates cation secretion, and this will appear to reduce the total anion secretion. From the data we conclude that genistein activates Cl Ϫ secretion through CFTR in the wild-type colon because the increase in I sc was inhibited by furosemide and DPC and because no Ca 2ϩ -dependent Cl Ϫ channel is present in the apical membrane of the distal colon epithelium (3).
Genistein decreased I sc when added to the colon from CF null and ⌬F508 mice. This was followed by a further decrease in response to forskolin in both genotypes, and the combined decrease in current was not significantly different from the decrease in I sc caused by forskolin alone. This finding suggests that genistein is activating the same K ϩ secretion pathway as forskolin (5). There was also no difference in the overall response to genistein and forskolin in the CF null and ⌬F508 colons, although the response to forskolin after genistein addition was significantly greater in the ⌬F508 colon compared with the CF null colon. The simplest explanation is that this is due to the tendency for the ⌬F508 colon to show a smaller response to genistein than CF null colon, resulting in the ability of forskolin to have a larger effect before the tissue reached its maximum response.
The basal I sc of ⌬F508 colons, although not the basal I sc of CF null colons, was significantly smaller than that of wild-type colons. This was due to hypoabsorption of Na ϩ , because the amiloride-sensitive current was less in ⌬F508 colons than in wild-type colons. This result differs from that of a previous report by Grubb and Boucher (11) , which showed that distal colon from the Cftr tm1UNC CF null mouse had a significantly lower basal I sc than wild-type tissue because of a lack of Cl Ϫ and HCO 3 Ϫ secretion. Also, the distal colon of wild-type mice in the Grubb and Boucher study had an approximately fourfold higher basal I sc compared with the wild-type mice used in this study, and neither wildtype nor Cftr tm1UNC tissue showed significant amiloride sensitivity under normal dietary conditions. The different results of the two studies could reflect differences in the level and/or regulation of the relevant ion channels due to the different genetic backgrounds of the two stocks. Interestingly, our study also found that there was no difference in the amiloride sensitivity of tracheas from wild-type, CF null, and ⌬F508 mice, unlike human CF airway tissue, which normally demonstrates hyperabsorption of Na ϩ . This finding suggests that the interaction of CFTR and ENaC may be different between mice and humans and that in the tracheal epithelium of mice from Cftr tm1Cam and Cftr tm2Cam stocks, CFTR does not act as a negative regulator of ENaC.
In conclusion, we have demonstrated that genistein can increase I sc in wild-type murine tracheas and colons and some ⌬F508 tracheas but not in CF null murine tracheas or CF null and ⌬F508 colons. Together with the data from Cl Ϫ channel blockers and low-Cl Ϫ buffer, the results strongly suggest that the increase in I sc is due to Cl Ϫ secretion through CFTR. The lack of a genistein-sensitive I sc in CF null tracheas compared with the wild type provides an alternative procedure to distinguish the two genotypes that is more selective than forskolin, which also activates Ca 2ϩ -mediated Cl Ϫ secretion. This allows CF null tracheas to be used from mice of any age to test strategies to restore a CFTR channel to the tracheal epithelium. The genistein-sensitive I sc seen in some ⌬F508 tracheas suggests that these mice may be useful for studying the action of genistein and other flavonoids on ⌬F508 protein, which may lead to clinical applications.
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